Suppr超能文献

用于快速检测肠杆菌科细菌中bla bla、bla bla和PBP3插入片段的五重PCR检测方法的开发与验证。

Development and validation of a pentaplex PCR assay for rapid detection of bla bla, bla bla and the PBP3 insert in Enterobacterales.

作者信息

Bakthavatchalam Yamuna Devi, Abdullah Fizaa, Srinivasan Devishree, Nithiyanandam Sangeetha, Neeravi Ayyanraj, Shah Poojah, Subburaju Nivedhana, Jaganathan Subha Vajjiravelu, Devi Rema, Nataraj Gita, Yesudason Binesh Lal, Walia Kamini, Veeraraghavan Balaji

机构信息

Department of Clinical Microbiology, Christian Medical College, Vellore, India.

Department of Infectious Disease, Christian Medical College, Vellore, India.

出版信息

Indian J Med Microbiol. 2024 Nov-Dec;52:100710. doi: 10.1016/j.ijmmb.2024.100710. Epub 2024 Aug 30.

Abstract

BACKGROUND

There is a high diversity of beta-lactamases in gram negative pathogens, making them difficult to treat. In the presence of OXA-1 and ampC, PTZ is no longer clinically relevant when treating Enterobacterales expressing ESBLs. Further, MBL infections are often treated with the combination of ceftazidime/avibactam with aztreonam. . It has recently been reported that NDM-expressing E. coli isolates co-harboring PBP3 insert develops resistance to this triple combination.

METHODS

A pentaplex PCR is developed and validated to simultaneously detect bla, bla, bla, bla, and the PBP3 insert in whole genome sequenced E. coli and K. pneumoniae isolates. In addition, the isolates chosen for pentaplex PCR evaluation were tested for their minimum inhibitory concentrations (MICs) against piperacillin/tazobactam, cefoperazone/sulbactam (C/S), ertapenem, imipenem, meropenem, ceftazidime/avibactam, aztreonam/avibactam, cefepime/taniborbactam, and cefiderocol.

RESULTS

The developed pentaplex PCR showed 100 % reproducibility with the antimicrobial resistance profile generated from whole genome sequenced data. PTZ and C/S are not effective against ESBL and/or OXA-1 expressing E. coli and K. pneumoniae isolates and do not offer any activity against CMY co-producers. Further, the combined effect of CMY, NDM and PBP3 inserts impacts aztreonam/avibactam activity and reduces the susceptibility to 40 % in E. coli isolates. While, aztreonam/avibactam showed potent activity against NDM-expressing K. pneumoniae isolates. Importantly, cefepime/taniborbactam and cefiderocol showed limited activity against NDM-expressing E. coli and K. pneumoniae isolates.

CONCLUSION

The pentaplex PCR was effective in detecting four beta-lactamases (bla, bla, bla, bla) as well as PBP3 inserts. It is expected that using pentaplex PCR as a diagnostic test for resistance detection in clinical practice will improve patient outcomes by providing prompt and targeted treatment.

摘要

背景

革兰氏阴性病原体中的β-内酰胺酶具有高度多样性,使其难以治疗。在存在OXA-1和ampC的情况下,在治疗表达超广谱β-内酰胺酶(ESBLs)的肠杆菌科细菌时,哌拉西林他唑巴坦(PTZ)在临床上不再具有相关性。此外,金属β-内酰胺酶(MBL)感染通常用头孢他啶/阿维巴坦与氨曲南联合治疗。最近有报道称,同时携带PBP3插入片段的表达新德里金属β-内酰胺酶(NDM)的大肠杆菌分离株对这种三联组合产生耐药性。

方法

开发并验证了一种五重PCR,用于在全基因组测序的大肠杆菌和肺炎克雷伯菌分离株中同时检测bla、bla、bla、bla和PBP3插入片段。此外,对选择用于五重PCR评估的分离株进行了针对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦(C/S)、厄他培南、亚胺培南、美罗培南、头孢他啶/阿维巴坦、氨曲南/阿维巴坦、头孢吡肟/他尼硼巴坦和头孢地尔的最低抑菌浓度(MICs)测试。

结果

所开发的五重PCR与从全基因组测序数据生成的抗菌药物耐药谱显示出100%的重现性。PTZ和C/S对表达ESBL和/或OXA-1的大肠杆菌和肺炎克雷伯菌分离株无效,并且对共产生CMY的菌株没有任何活性。此外,CMY、NDM和PBP3插入片段的联合作用影响氨曲南/阿维巴坦的活性,并使大肠杆菌分离株的敏感性降低至40%。同时,氨曲南/阿维巴坦对表达NDM的肺炎克雷伯菌分离株显示出强效活性。重要的是,头孢吡肟/他尼硼巴坦和头孢地尔对表达NDM的大肠杆菌和肺炎克雷伯菌分离株显示出有限的活性。

结论

五重PCR可有效检测四种β-内酰胺酶(bla、bla、bla、bla)以及PBP3插入片段。预计在临床实践中使用五重PCR作为耐药性检测的诊断测试,将通过提供及时和有针对性的治疗来改善患者的治疗结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验